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Edited by Alex TokerWithin the AGC kinase superfamily, gene fusions resulting
from chromosomal rearrangements have been most frequently
described for protein kinase C (PKC), with gene fragments
encoding either the C-terminal catalytic domain or the N-ter-
minal regulatory moiety fused to other genes. Kinase fusions
that eliminate regulatory domains are typically gain of function
and often oncogenic. However, several quality control path-
ways prevent accumulation of aberrant PKC, suggesting that
PKC fusions may paradoxically be loss of function. To explore
this topic, we used biochemical, cellular, and genome editing
approaches to investigate the function of fusions that retain the
portion of the gene encoding either the catalytic domain or
regulatory domain of PKC. Overexpression studies revealed
that PKC catalytic domain fusions were constitutively active
but vulnerable to degradation. Genome editing of endogenous
genes to generate a cancer-associated PKC fusion resulted in
cells with detectable levels of fusion transcript but no detect-
able protein. Hence, PKC catalytic domain fusions are para-
doxically loss of function as a result of their instability,
preventing appreciable accumulation of protein in cells.
Overexpression of a PKC regulatory domain fusion suppressed
both basal and agonist-induced endogenous PKC activity,
acting in a dominant-negative manner by competing for diac-
ylglycerol. For both catalytic and regulatory domain fusions,
the PKC component of the fusion proteins mediated the effects
of the full-length fusions on the parameters examined, sug-
gesting that the partner protein is dispensable in these con-
texts. Taken together, our findings reveal that PKC gene
fusions are distinct from oncogenic fusions and present a
mechanism by which loss of PKC function occurs in cancer.
Protein kinase C (PKC) plays a critical role in cellular ho-
meostasis, transducing signals initiated by receptor-mediated
hydrolysis of phospholipids to regulate cellular processes
such as apoptosis, migration, and proliferation (1–3). With its
activity finely tuned, dysregulation of PKC has been implicated* For correspondence: Alexandra C. Newton, anewton@health.ucsd.edu.
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BY license (http://creativecommons.org/licenses/by/4.0/).in a multitude of diseases, including metabolic disorders,
neurodegeneration, and most notably, cancer (4–6). Since PKC
was identified as a high-affinity receptor for the tumor-
promoting compounds phorbol esters in the 1980s, it was
ascribed an oncogenic role (7–9). However, recent analysis of
cancer-associated point mutations in PKC revealed that they
are generally loss of function (10). Additionally, germline
mutations in one isozyme, PKCδ, are responsible for a lym-
phoproliferative disorder (11–13). Furthermore, high protein
levels of PKC are associated with improved survival in diverse
cancers, including colon cancer (14), pancreatic cancer (15),
and non-small-cell lung carcinoma (16), reframing PKC as
providing a tumor suppressive function (17). Gene fusions
involving PKC have also been identified in cancer. Analysis of
RNA sequencing data from The Cancer Genome Atlas
(TCGA) reveals that approximately 15% of in-frame kinase
fusions belong to members of the AGC superfamily of serine/
threonine kinases, second only to the tyrosine kinase family
(18). Within the AGC kinases, the greatest abundance of gene
fusions occurs in the PRKC genes (18).
The PKC family, encoded by the PRKC genes, consists of
nine isozymes, categorized into three classes: conventional (α,
β, γ), novel (δ, ε, η, θ), and atypical (ζ, ι/λ) (19). They all possess
a C-terminal kinase domain that is constrained by a pseudo-
substrate segment in the N-terminal regulatory moiety, serving
to autoinhibit the enzyme in the absence of its second mes-
sengers. Release of autoinhibition occurs following engage-
ment of the appropriate second messengers to membrane-
targeting modules in the regulatory moiety. Conventional
and novel isozymes of PKC are activated by binding of diac-
ylglycerol (DAG) to one of their tandem C1 domains, with
conventional isozymes also requiring binding of Ca2+ to their
C2 domain for activation. Atypical isozymes respond to
neither DAG nor Ca2+ but contain a protein-binding PB1
domain that mediates protein–protein interactions (20).
Before PKC is catalytically competent, it is matured by a series
of ordered phosphorylations that are necessary for the enzyme
to adopt an autoinhibited conformation; these are the activa-
tion loop (Thr500 in PKCβII), the turn motif (Thr641 in
PKCβII), and the hydrophobic motif (Ser660 in PKCβII) (21).
Of these, phosphorylation of the hydrophobic motif is indis-
pensable for autoinhibition, and dephosphorylation of this siteJ. Biol. Chem. (2021) 296 100445 1
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Protein kinase C fusions in cancerby the PH domain leucine-rich repeat protein phosphatase
PHLPP shunts PKC to degradative pathways (22). Thus, this
autoinhibited conformation is dependent upon phosphoryla-
tion and is critical to ensuring PKC stability. Aberrant PKC
that is not properly autoinhibited is degraded, subject to
PHLPP-mediated quality control of PKC. This quality control
presents a major mechanism for loss of PKC function in cancer
(15). Thus, cancer-associated mutations that disrupt auto-
inhibitory constraints are paradoxically loss of function
because the constitutively active kinase is sensitive to degra-
dation. This raises the question as to whether cancer-
associated fusions in which the pseudosubstrate is replaced
by a fusion partner will be unstable or whether they have
mechanisms to evade quality control degradation.
Here, we investigated PKC gene fusions that yield proteins
retaining the catalytic domain of PKC (3’ PKC fusions) as well
as fusions that yield proteins retaining the regulatory domain
of PKC (5’ PKC fusions). Cell-based assays revealed that the
overexpressed catalytic domain fusions were constitutively

















































( , , )
Novel











Figure 1. Fusions of the protein kinase C regulatory and catalytic moietie
PKC subclasses, including pseudosubstrate (red), C1 domains (orange), C2 doma
terminal regulatory domain followed by a conserved C-terminal catalytic doma
sites necessary for catalytic competency are indicated (pink, orange, and gre
Chromosome Aberrations and Gene Fusions in Cancer, the TCGA Tumor Fusio
fusions for each PKC isozyme is depicted. C, curated PKC fusions in (B) cate
histiocytoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcin
cinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse larg
tiforme; HNSC, head and neck squamous cell carcinoma; KIRC, clear cell ren
myeloid leukemia; LGG, low-grade glioma; LIHC, liver hepatocellular carcinom
medulloblastoma; OV, ovarian serous cystadenocarcinoma; PCPG, pheochrom
prostate adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; S
UCEC, uterine corpus endometrial carcinoma.
2 J. Biol. Chem. (2021) 296 100445these fusions were unstable. Utilizing CRISPR/Cas9-mediated
gene editing to encode an endogenous 3’ PKC fusion, we
were able to detect the fusion at the mRNA level in CRISPR-
edited cells but not at the protein level, consistent with the
fusion protein being too unstable to accumulate in cells.
Analysis of a 5’ PKC fusion encoding the regulatory domain of
PKC, with complete loss of the kinase domain, revealed that it
functioned in a dominant-negative manner to suppress
endogenous PKC activity. Taken together, these results iden-
tify PKC fusions as a mechanism for loss of PKC function in
cancer.Results
A multitude of PKC fusions have been identified in cancer
In order to assess the landscape of PKC fusions in cancer,
we queried the literature and several online databases to curate
a comprehensive list of all PKC gene fusions identified from
patient tumor samples (Table S1) (18, 23–37). The online




































































































s are detected in a multitude of cancers. A, domain structure of the three
in (yellow), and kinase domain (cyan). PKC structure consists of a variable N-
in. The activation loop, turn motif, and hydrophobic motif phosphorylation
en, respectively). B, curated from the literature, the Mitelman Database of
n Gene Data Portal, ChimerDB v3.0, and COSMIC, number of 5’ and 3’ gene
gorized by cancer type in which they were detected. BFH, benign fibrous
oma; CESC, cervical squamous cell carcinoma and endocervical adenocar-
e B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma mul-
al cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute
a; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MB,
ocytoma and paraganglioma; PGNT, papillary glioneuronal tumor; PRAD,
TAD, stomach adenocarcinoma; TALL, T-cell acute lymphoblastic leukemia;
Figure 2. 3’ PKC fusions yield proteins that are unphosphorylated at the PKC priming sites yet constitutively active. A, schematic of wild-type and
PKC fusion constructs used in this study. B, immunoblot analysis of lysates from COS7 cells transfected with the indicated YFP-tagged constructs. Blots
probed with the indicated total PKC or phospho-specific antibodies. Arrow indicates border between stacking and separating gel. Data are representative of
three independent experiments. C, analysis of agonist-induced PKC activity in COS7 cells transfected with CKAR alone (Endogenous) or cotransfected with
the indicated mCherry-tagged PKC construct. Cells treated with agonists UTP (100 μM), PDBu (200 nM), and either inhibitor Gӧ6976 or Gӧ6983 (1 μM).
Graphs depict normalized FRET ratio changes (mean ± SEM) from three independent experiments. D, analysis of basal PKC activity in COS7 cells transfected
with CKAR alone (Endogenous) or cotransfected with the indicated mCherry-tagged PKC construct. Cells treated with inhibitor BisIV (2 μM) or Gӧ6983
(1 μM). Graphs depict normalized FRET ratio changes (mean ± SEM) from three independent experiments.
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Protein kinase C fusions in cancerof Chromosome Aberrations and Gene Fusions in Cancer, the
TCGA Tumor Fusion Gene Data Portal, ChimerDB v3.0, and
the Catalogue of Somatic Mutations in Cancer (COSMIC)
(30, 38–40). With this list of fusions, we were able to ascertain
that each of the nine isozymes from the three subclasses of the
PKC family (Fig. 1A) was detected in at least one gene fusion
(Fig. 1B). Although there were only seven isozymes for which
there were fusions detected that retained the 5’ end of PKC,
there were fusions detected for all isozymes where the 3’ end of
PKC was retained. The greatest number of fusions was
detected for PRKCA with 43 fusions identified, and the ma-
jority of these (19 fusions) were found in breast cancer sam-
ples. In total, 102 fusions were identified across all PKC family
members. PKC gene fusions were detected in 26 different
cancer types, from benign fibrous histiocytoma (BFH) to
uterine corpus endometrial carcinoma (UCEC) (Fig. 1C).
Among these different cancer types, the greatest number of
PKC gene fusions was identified in breast invasive carcinoma
(BRCA) with 31 fusions detected and lung adenocarcinoma
(LUAD) with nine fusions detected. Notably, approximately
half of these fusions resulted in products that were out of
frame (Table S1). Several of the fusions were detected in
different cancer types, and a few fusions were recurrent
(Table S2). Given that PKC is the most abundantly fused AGC
kinase and the fusions were detected in a multitude of cancers,
we sought to determine how these fusions might affect PKC
signaling and contribute to tumorigenesis. To this end, we
selected three 3’ fusions (TANC2-PRKCA, SLC44A1-PRKCA,
and GGA2-PRKCB) and one 5’ fusion (PRKCA-CDH8) in this
study for further analysis (18, 34–37, 41).PKC catalytic domain fusions are unphosphorylated yet
constitutively active
3’ PKC gene fusions yield proteins in which the N-terminal
regulatory domain of PKC is truncated and replaced with the
N-terminal domain of its gene partner. The 3’ fusions TANC2-
PRKCA, SLC44A1-PRKCA, and GGA2-PRKCB, found in lung
squamous cell carcinoma (LUSC), papillary glioneuronal tu-
mors (PGNT), and low-grade glioma (LGG), respectively, were
selected for biochemical analysis (Fig. 2A) (34–37). TANC2-
PRKCA encodes the first 45 amino acid residues of TANC2
fused to the last 496 residues of PKCα, and SLC44A1-PRKCA
encodes the first 650 residues of CTL1 fused to the last 366
residues of PKCα. GGA2-PRKCB encodes the first 158 resi-
dues of GGA2 fused to the last 605 residues of PKCβII.
TANC2 has been identified as a scaffolding protein in den-
dritic spines, and CTL1 functions as a choline transporter
(42–44). GGA2 is part of the Golgi-localized, gamma adaptin
ear-containing, ARF-binding (GGA) family of adaptor pro-
teins, which localize to the trans-Golgi network and regulate
protein trafficking (45). The protein products resulting from
the fusion transcripts retain the complete catalytic domain of
PKC with some portion of the regulatory domain. Specifically,
TANC2-PKCα retains the C2 domain and GGA2-PKCβII re-
tains the C1B and C2 domains, whereas CTL1-PKCα only
retains part of the hinge between the regulatory and catalytic4 J. Biol. Chem. (2021) 296 100445moieties. Notably, the autoinhibitory pseudosubstrate, located
at the N terminus, is lost in all three fusion proteins. In our
biochemical analysis of these catalytic domain fusions, we also
analyzed N-deletion proteins in which we delete the fusion
partner and retain only the PKC portion of the fusion. Addi-
tionally, we analyzed a variant of the CTL1-PKCα fusion
protein in which there was an internal deletion within CTL1
(35).
Phosphorylation at the three PKC priming sites, the acti-
vation loop, turn motif, and hydrophobic motif, is necessary
for catalytic competency. Thus, we determined whether the
fusion proteins and their variants are also phosphorylated at
these sites. Whereas wild-type PKC was constitutively phos-
phorylated at all three processing sites, the full-length fusion
proteins TANC2-PKCα, CTL1-PKCα, and GGA2-PKCβII
were not (Fig. 2B). The PKCα and PKCβII N-deletion proteins,
comprising only the PKC portion of the fusion, as well as the
CTL1-PKCα internal deletion (Int. Del.) protein, were also not
appreciably phosphorylated at the activation loop, turn motif,
or hydrophobic motif; neither were constructs in which the
pseudosubstrate was deleted (ΔPS). We have previously re-
ported that mutations that impair autoinhibition of PKC pre-
vent retention of phosphate at the priming sites (15). Lack of
phosphorylation at the priming sites of these proteins is
consistent with that of PKCα and PKCβII proteins where the
pseudosubstrate is deleted (ΔPS). In summary, both the full-
length fusion proteins and the N-deletion proteins lacked
phosphorylation at the priming sites.
We next addressed whether the fusion proteins exhibited
catalytic activity, as assessed with the genetically encoded,
fluorescence resonance energy transfer (FRET)-based reporter
for PKC activity, C kinase activity reporter (CKAR) (46).
Stimulation of COS7 cells expressing mCherry-tagged wild-
type PKC (blue) resulted in a transient increase in CKAR
phosphorylation upon treatment with the physiological agonist
UTP, which generates Ca2+ and DAG. Subsequent treatment
with the phorbol ester PDBu resulted in maximal, sustained
activity, which was abolished upon addition of PKC inhibitor,
either Gӧ6976 or Gӧ6983 (Fig. 2C). In contrast, the full-length
fusion proteins (red) were maximally active under basal con-
ditions and did not respond to the addition of UTP or PDBu.
However, addition of inhibitor reduced activity to baseline
levels observed following inhibition of wild-type enzyme.
Introduction of a mutation to render the PKC kinase domain
catalytically dead (V353F in PKCα and V356F in PKCβ, gray)
abolished the constitutive activity of the full-length fusion
proteins (47, 48). Moreover, similar results were obtained for
the N-deletion proteins that comprised only the PKC segment
of the fusions (N-Del., yellow). To further probe the basal
activity of the fusion proteins, COS7 cells expressing either
CKAR alone (white) or coexpressing mCherry-tagged PKC
were treated with a PKC inhibitor alone (BisIV or Gӧ6983)
(Fig. 2D). Inhibitor treatment resulted in only a modest
reduction in PKC activity for cells expressing wild-type PKC
(blue), consistent with effective autoinhibition in the absence
of second messengers. In contrast, addition of inhibitor in cells
overexpressing the full-length fusion proteins (red) or the PKC
Protein kinase C fusions in cancercomponent of the fusions (yellow) resulted in a robust
reduction in CKAR phosphorylation, indicating high basal
activity. This activity was abolished when introducing the
mutation rendering the kinase domain catalytically dead
(gray). Thus, although the full-length fusion and N-deletion
proteins were unphosphorylated at the PKC priming sites, they
exhibited constitutive, agonist-independent activity.
Phosphorylation at the hydrophobic motif is necessary for
PKC maturation, leading us to ask whether the fusion proteins
had been phosphorylated during their maturation but wereB
A
Figure 3. The open conformation that renders PKC catalytic domain fusi
immunoblot analysis of lysates from COS7 cells transfected with the indicat
harvested at the indicated timepoints. Blots probed for indicated PKC and β-
while asterisk depicts faster mobility unphosphorylated PKC. For quantification,
representative, and graphs depict mean ± SEM from three independent expe
wild-type PKC and the fusion, and # indicates significance between wild-type P
COS7 cells transfected with HA-tagged ubiquitin alone or cotransfected with in
for 30 min. Blots probed for HA to assess ubiquitination of wild-type PKC
experiments.unable to retain the phosphate because of their inability to
autoinhibit. Mutation of the hydrophobic motif Ser to Ala in
TANC2-PKCα (S657A in wild-type PKCα, pink) or GGA2-
PKCβII (S660A in wild-type PKCβII, pink) reduced basal ac-
tivity to levels comparable with those of wild-type PKC
(Fig. S1, A and B, respectively). In contrast, mutation of the
turn motif in either fusion protein to the phosphomimetic
residue Glu (T638E in wild-type PKCα and T641E in wild-type
PKCβII, green) resulted in expression of proteins with high
basal activity. Mutation of the hydrophobic motif in TANC2-ons constitutively active also causes them to be markedly unstable. A,
ed YFP-tagged constructs, treated with cycloheximide (CHX, 355 μM), and
actin. For wild-type PKC, dash depicts slower mobility phosphorylated PKC
PKC protein levels normalized to loading control and then to t = 0. Blots are
riments. *p < 0.05 (Student’s t-test). Asterisk indicates significance between
KC and PKC ΔPS. B, immunoblot analysis of PKCα immunoprecipitates from
dicated YFP-tagged PKC and treated with PDBu (200 nM) or vehicle (DMSO)
compared with the fusion. Data are representative of three independent
J. Biol. Chem. (2021) 296 100445 5
Protein kinase C fusions in cancerPKCα to Glu (S657E in wild-type PKCα, orange) also resulted
in protein with high basal activity. The lack of significant ac-
tivity with fusions containing an Ala at the hydrophobic motif
is consistent with previous studies indicating that phosphor-
ylation at this site during PKC maturation is necessary for
activity (15). To confirm that these fusions have the intrinsic
ability to become phosphorylated at this site, the GGA2-
PKCβII fusion was expressed in insect cells, a system where
low PHLPP activity permits retention of phosphate on aber-
rant PKC (49). Like wild-type PKCβII, GGA2-PKCβII fusion
protein purified from baculovirus-infected insect cells was
phosphorylated at all three processing sites (Fig. S1C). This is
consistent with lack of phosphate at these sites in mammalian
cells resulting from the previously described quality control
mechanism mediated by PHLPP.
Fusions of the PKC catalytic domain are unstable
Prolonged activation of PKC, such as that which occurs with
phorbol ester treatment, ultimately results in PKC down-
regulation and degradation (50, 51). To determine whether the
constitutively active PKC fusion proteins are also sensitive to
degradation, COS7 cells overexpressing YFP-tagged wild-type
PKC, fusion protein, or pseudosubstrate-deleted PKC were
treated with cycloheximide to inhibit protein synthesis, and
degradation of the existing PKC protein was monitored
(Fig. 3A). Wild-type PKCα and PKCβII degraded slowly, with
over half the protein remaining after 48 h treatment with
cycloheximide. In contrast, the TANC2-PKCα and GGA2-
PKCβII fusion proteins turned over more rapidly, with little
to no protein detected at 24 h. Deletion of the pseudosubstrate
(ΔPS) in both PKCα and PKCβII resulted in rapid turnover,
comparable with that observed for the fusion proteins. Note
that the minor species of unphosphorylated wild-type PKCβII
(Fig. 3A, lower panel, asterisk) was rapidly degraded, similar to
that of the fusion and ΔPS proteins. Immunoblot analysis of
GGA2-PKCβII fusion protein purified from HEK 293T cells
revealed that it was associated with the molecular chaperones
Hsp90, Hsp70, and Cdc37 (Fig. S2, A and B). This suggests that
the fusion protein maintains an open conformation that per-
mits binding of these chaperones (52–54). Thus, these data
demonstrate that the fusion proteins are intrinsically unstable,
consistent with our previous studies revealing that lack of
phosphate at the hydrophobic motif targets PKC for
degradation.
Given that the fusion proteins were observed to be more
sensitive to degradation, we next asked whether they were
more ubiquitinated than wild-type PKC. To address this, we
performed a cellular ubiquitination assay in which we over-
expressed ubiquitin alone or in conjunction with wild-type
PKCα or the TANC2-PKCα fusion in COS7 cells, immuno-
precipitated the PKC protein, and assessed the degree of
ubiquitination (Fig. 3B). Additionally, we compared cells
treated with the phorbol ester PDBu to vehicle (DMSO), as
treatment with phorbol esters promotes ubiquitination and
ultimately results in PKC degradation. In basal conditions,
TANC2-PKCα was significantly more ubiquitinated than wild-6 J. Biol. Chem. (2021) 296 100445type PKCα (lane 5 versus lane 3). Treatment with PDBu
induced ubiquitination of wild-type PKCα but had no effect on
the ubiquitination of the fusion protein, which lacks the do-
mains necessary to bind PDBu. These results indicate that the
unstable fusion protein is more ubiquitinated compared with
wild-type PKC, in accordance with its enhanced sensitivity to
degradation.
CRISPR-edited cells exhibit detectable PKC fusion mRNA but
not protein
Given the instability of the catalytic domain fusion proteins,
we sought to determine whether they would be detected when
expressed at the endogenous locus. To accomplish this, we
utilized CRISPR/Cas9-mediated gene editing to engineer the
TANC2-PRKCA fusion from the endogenous genes in the
MDA-MB-231 breast cancer cell line (Fig. 4A) (55, 56).
Employing two guide RNAs, one directed at an intron of
TANC2 and one directed at an intron of PRKCA, we generated
a heterozygous clone (CRISPR Clone #93) with one wild-type
allele of PRKCA and one allele of the TANC2-PRKCA fusion.
We first validated expression of TANC2-PRKCA at the mRNA
level by amplifying a product at the fusion junction. The fusion
mRNA was detected in cells of the CRISPR-edited clone but
not the parental cell line (Fig. 4B). Next, we examined
expression of TANC2 and PRKCA, targeting the 5’ and 3’ ends
of each mRNA, which would correspond to the respective “N-
Term” and “C-Term” of the resulting proteins. Compared with
the parental MDA-MB-231 cells, the CRISPR-edited cells
exhibited an increase in expression of the TANC2 “N-Term”
product and a decrease in expression of the “C-Term” product
(Fig. 4C). A decrease in expression of the TANC2 “C-Term”
product is in concordance with the fusion-expressing cells
containing only one copy of wild-type TANC2, whereas the
increase in expression of the TANC2 “N-Term” product may
reflect compensatory upregulation from loss of the other copy
of TANC2. Probing for PRKCA expression in the parental and
CRISPR-edited cells revealed the reverse; expression of the
PRKCA “N-Term” product was decreased in the fusion-
expressing cells, whereas expression of the “C-Term” prod-
uct was increased (Fig. 4D). In this case, the decrease in
expression of the “N-Term” product in the fusion-expressing
cells can be attributed to loss of a copy of wild-type PRKCA,
and as with the TANC2 “N-Term” product, the increase in
expression of the PRKCA “C-Term” product may reflect
compensatory upregulation. Consistent with upregulation of
the wild-type alleles, increased PRKCA expression was re-
ported in the tumor in which the fusion was originally detected
(34).
Upon confirmation of TANC2-PRKCA expression in the
CRISPR-edited cells, we next assessed whether the fusion
could be detected at the protein level. Both TANC2 and
PKCα protein were readily detected in the parental MDA-
MB-231 cells and in the cells of the fusion-expressing clone,
with lower expression in the fusion-expressing clone
consistent with loss of one allele (Fig. 4E). Importantly, the




Figure 4. The TANC2-PRKCA fusion is detected at the mRNA level but not the protein level in CRISPR-edited cells. A, schematic illustrating strategy to
generate cells expressing the TANC2-PRKCA fusion via CRISPR/Cas9 gene editing. B, mRNA expression of the TANC2-PRKCA fusion and actin (ACTB) in the
parental and CRISPR-edited clone analyzed by RT-PCR. Product indicated by black bar on schematic. Reactions analyzed on agarose gel, with each lane
representing an individual replicate. C, TANC2 mRNA expression at the 5’ (“N-Term”) and 3’ (“C-Term”) ends in the parental and CRISPR-edited clone
analyzed by RT-qPCR and normalized to actin (ACTB). Products indicated by black bars on schematic. Data represent means ± SEM from at least three
independent experiments. **p < 0.01 (Student’s t-test). D, PRKCA mRNA expression at the 5’ (“N-Term”) and 3’ (“C-Term”) ends in the parental and CRISPR-
edited clone analyzed by RT-qPCR and normalized to actin (ACTB). Products indicated by black bars on schematic. Data represent means ± SEM from at least
three independent experiments. **p < 0.01, ***p < 0.001 (Student’s t-test). E, immunoblot analysis of lysates from parental and CRISPR-edited cells, probed
for TANC2, PKCα, and α-tubulin. Arrow indicates predicted mobility of the fusion protein. Data are representative of three independent experiments.
Protein kinase C fusions in cancer65 kDa, was not detected in the CRISPR-edited cells (ex-
pected position indicated by arrow). This suggests that the
fusion protein is indeed too unstable to appreciably accu-
mulate in an endogenous context. We then sought to
determine whether degradation of the fusion protein could
be slowed. Inhibition of proteasomal (Fig. S3A) or endo-
somal/lysosomal (Fig. S3B) degradative pathways in our
overexpression studies with cycloheximide did not slow
degradation of the TANC2-PKCα fusion protein.Additionally, knockdown of RINCK, the E3 ligase that cat-
alyzes ubiquitin-mediated degradation of wild-type PKC, as
well as CHIP, a “quality control” E3 ligase that cooperates
with molecular chaperones to ubiquitinate unfolded pro-
teins, did not allow for accumulation of the protein in the
CRISPR-edited cells (Fig. S4) (57, 58). These data thus sug-
gest that the unstable fusion protein is degraded through a
separate, proteasome- and endosome-independent mecha-
nism. Importantly, the fusion protein is paradoxically loss ofJ. Biol. Chem. (2021) 296 100445 7
Protein kinase C fusions in cancerfunction as it is unable to accumulate to detectable levels in
cells in an endogenous context.
CRISPR-edited fusion cells exhibit reduced apoptosis
To determine the functional relevance of the catalytic
domain fusion, whose expression would invariably result in the
loss of PKC activity, we addressed whether there was any
difference in apoptosis between the parental MDA-MB-
231 cells and the CRISPR-edited fusion cells. The initiation of
programmed cell death is characterized by proteolytic cleavage
and consequent activation of proteases such as caspase-3 (59,
60). We thus assessed basal apoptosis in the two cell lines by
probing for levels of cleaved caspase-3 (Fig. 5A). Compared
with the parental cells, cells expressing the TANC2-PRKCA
fusion exhibited decreased levels of cleaved caspase-3 (lane 1
versus lane 2). To determine whether this resulted from loss of
PKC, we also generated a heterozygous knockout of PKCα in
the MDA-MB-231 cell line and assessed levels of cleaved
caspase-3. As with the fusion-expressing cells, the heterozy-
gous PKCα knockout cells had reduced levels of cleaved
caspase-3 compared with parental cells (lane 3 versus lane 1).
This suggests that the decreased cleaved caspase-3 levels
observed in the fusion-expressing line resulted from loss of
PKC activity. To confirm that the decreased cleaved caspase-3
reflected decreased apoptosis, we performed an apoptosis
assay that measures cell-surface-exposed phosphatidylserine,
detected by luminescence of bound annexin V-luciferase
(Fig. 5B). Over the course of 10 h, both the fusion-expressing
(purple) and heterozygous knockout (orange) cells exhibited
significantly lower levels of apoptosis compared with the
parental cells (gray), with similar levels of apoptosis between
the CRISPR-edited lines. We also assessed apoptosis in the cell
lines following treatment with etoposide or vehicle (DMSO)A B
Figure 5. TANC2-PRKCA-expressing cells exhibit reduced levels of cleaved c
parental, CRISPR-edited TANC2-PKCα fusion, and heterozygous PKCα knockou
representative of three independent experiments. B, apoptosis assay performed
or heterozygous PKCα knockout (orange) cells. Data represent luminescence
dylserine as a function of time following addition of reagents. Graph depicts m
(Student’s t-test). Asterisk indicates significance between parental and fusion-e
zygous PKCα knockout cells. C, apoptosis assay described in (B) was performed
or heterozygous PKCα knockout (orange) cells treated with etoposide (12.5 μ
dependent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-te
conditions for each cell line. # and % indicate significance between the pa
basal and etoposide-treated conditions, respectively.
8 J. Biol. Chem. (2021) 296 100445for 24 h (Fig. 5C). Whereas etoposide significantly increased
apoptosis in all three cell lines compared with their respective
vehicle-treated controls, the fusion cells and heterozygous
knockout cells continued to have significantly lower levels of
apoptosis compared with the parental cells. Etoposide-induced
apoptosis in the fusion and heterozygous knockout cells
reached levels comparable with that of the vehicle-treated
parental cells (basal apoptosis). Altogether, these results indi-
cate that expression of the 3’ PKC fusion and subsequent loss
of PKC activity suppress basal apoptosis, conditions that would
promote a hallmark of cancer—cell survival.
PKC regulatory domain fusions are LOF and potentially
dominant-negative
Whereas PKC catalytic domain fusions are loss of function
because of their inherent sensitivity to degradation, regulatory
domain fusions are intrinsically loss of function because the
portion of the gene encoding the C-terminal kinase domain is
truncated. However, expression of these 5’ PKC fusions may
have functional consequences beyond loss of the catalytic
domain. Previous studies investigating loss-of-function muta-
tions in PKC demonstrated that kinase-dead mutants may act
in a dominant-negative manner (10). Thus, we addressed
whether 5’ PKC fusions, retaining various elements of the
regulatory moiety, can also be dominant-negative. For our
biochemical analyses, we selected the fusion PRKCA-CDH8,
originally detected in breast cancer (Fig. 6A) (18, 30, 41).
PRKCA-CDH8 translates to a protein containing the first 306
amino acid residues of PKCα fused to the last 715 residues of
Cadherin-8 (CDH8). CDH8 is a type II classical cadherin that
mediates cell–cell adhesion and regulates proliferation of
cortical interneurons (61). The portion of PRKCA retained in
the fusion encodes the entire PKC regulatory moiety, includingC
aspase-3 and decreased apoptosis. A, immunoblot analysis of lysates from
t cells, probed for caspase-3, cleaved caspase-3, PKCα, and β-actin. Data are
on MDA-MB-231 parental (gray), CRISPR-edited TANC2-PKCα fusion (purple),
upon binding of annexin V-luciferase to cell-surface-exposed phosphati-
ean ± SEM from three independent experiments. **p < 0.01, ***p < 0.001
xpressing cells, and # indicates significance between parental and hetero-
on MDA-MB-231 parental (gray), CRISPR-edited TANC2-PKCα fusion (purple),
M) or vehicle (DMSO) for 24 h. Graph depicts mean ± SEM from three in-
st). Asterisk indicates significance between vehicle and etoposide-treated






Figure 6. 5’ PKC fusions act in a dominant-negative manner, suppressing the activity of wild-type PKC. A, schematic of wild-type and PKCα-CDH8
fusion construct used in this study. In addition to the full-length fusion, a C-deletion construct in which the C-terminal fusion partner is deleted was also
generated (PKCα C-Del.). B, analysis of agonist-induced PKC activity in COS7 cells transfected with CKAR alone (Endogenous) or cotransfected with the
indicated mCherry-tagged PKC construct. Cells treated with agonists UTP (100 μM), PDBu (200 nM), and inhibitor Gӧ6983 (1 μM). Graphs depict normalized
FRET ratio changes (mean ± SEM) from three independent experiments. C, analysis of agonist-induced PKC activity in COS7 cells transfected with the
reporter CKAR2 and either vector or the indicated mCherry-tagged PKC construct. Cells treated with UTP (100 μM). Graphs depict normalized FRET ratio
changes (mean ± SEM) from three independent experiments. D, analysis of basal PKC activity in COS7 cells transfected with CKAR alone (Endogenous) or
cotransfected with the indicated mCherry-tagged PKC construct. Cells treated with inhibitor Gӧ6983 (1 μM). Graphs depict normalized FRET ratio changes
(mean ± SEM) from four independent experiments. E, immunoblot analysis of lysates from COS7 cells transfected with the indicated YFP-tagged PKC and
treated with PDBu (200 nM) or vehicle (DMSO) for 30 min. Blots probed with antibodies for pSer PKC substrate and GFP. Quantification of pSer PKC substrate
signal normalized to loading control (Hsp90) depicts mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01 (Student’s t-test). F, images of
cells from (B) prior to drug addition depicting mCherry fluorescence for wild-type PKCα (top) and the PKCα-CDH8 fusion (bottom). Scale bar, 20 μm. G,
analysis of agonist-induced PKC activity at the Golgi in COS7 cells transfected with Golgi-targeted CKAR alone (Endogenous) or cotransfected with mCherry-
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Protein kinase C fusions in cancerthe inhibitory pseudosubstrate, the C1A and C1B domains,
and the C2 domain. In addition to analyzing the full-length
fusion, we also analyzed a C-deletion (C-Del.) variant con-
taining only the PKC portion of the fusion. First, we deter-
mined the effect of the regulatory fusion and the C-deletion
variant on endogenous PKC activity utilizing the genetically
encoded FRET reporter CKAR. Treatment of COS7 cells
expressing CKAR (white) with UTP resulted in a transient
increase in endogenous PKC activity, PDBu treatment caused a
greater, more sustained induction in PKC activity, and inhib-
itor treatment resulted in activity returning to baseline
(Fig. 6B). However, in cells coexpressing CKAR and the PKCα-
CDH8 fusion (red), the UTP-mediated increase in PKC activity
was reduced. A similar suppression of endogenous activity in
response to UTP was observed for the C-deletion protein
(yellow), which contains the isolated regulatory moiety of PKC.
Although the response to a physiological stimulus (UTP) was
significantly suppressed with expression of the regulatory
domain fusion, there was no change in PDBu-induced activity.
Expression of the C-deletion protein (yellow) suppressed
PDBu-induced activity.
Reasoning that the exposed C1 domains of regulatory
domain fusion proteins may suppress endogenous PKC ac-
tivity by sequestering DAG, we examined whether disabling
DAG binding abolished the inhibition of UTP-stimulated ac-
tivity by unmasked regulatory domains. To this end, we
introduced a single point mutation in each C1 domain to
disrupt DAG binding. Specifically, we mutated W58 and Y123
in the C1A and C1B domains of PKCβII, respectively, to Ala.
Coexpression of a catalytically inactive PKC (S660F) (15) with
C kinase activity reporter 2 (CKAR2) (62) resulted in sup-
pression of endogenous PKC activity upon UTP stimulation
(Fig. 6C, red). However, mutation of the C1 domains to disrupt
DAG binding abolished suppression of endogenous activity
(Fig. 6C, blue), resulting in activity similar to that of cells
transfected with vector alone (Fig. 6C, white). Mutation of
these residues also impeded UTP-induced translocation, a
consequence of the mutant’s inability to bind DAG (Fig. S5).
These data reveal that the dominant-negative effects of pro-
teins with exposed C1 domains specifically result from
sequestration of DAG.
To examine the effect of the fusion on basal activity, we
treated cells expressing CKAR alone (white) or coexpressing
the full-length fusion (red) or C-deletion protein (yellow) with
the PKC inhibitor Gӧ6983 (Fig. 6D). Expression of either
PKCα-CDH8 or the C-deletion variant suppressed endoge-
nous PKC activity, indicated by the smaller reduction in CKAR
phosphorylation compared with that of cells expressing the
reporter alone. Thus, these results show that the PKCα-CDH8
regulatory domain fusion and C-deletion variant are able to
suppress not only agonist-induced PKC activity but also basal
PKC activity.tagged PKCα-CDH8. Cells treated with agonists UTP (100 μM), PDBu (200 nM),
(mean ± SEM) from three independent experiments. H, analysis of basal PKC a
(Endogenous) or cotransfected with mCherry-tagged PKCα-CDH8. Cells treat
changes (mean ± SEM) from three independent experiments.
10 J. Biol. Chem. (2021) 296 100445To complement our FRET studies, we also examined the
effect of the PKC regulatory domain fusion on endogenous
PKC activity by probing for phosphorylation of PKC substrates
with a phospho-Ser PKC substrate antibody (Fig. 6E). We
compared nontransfected (NT) COS7 cells to COS7 cells
overexpressing YFP-tagged wild-type PKCα, PKCα-CDH8, or
the C-deletion variant in PDBu-treated and vehicle (DMSO)
conditions. In the vehicle-treated condition, we detected basal
phosphorylation in nontransfected cells that increased with
overexpression of wild-type PKCα. Between nontransfected
cells and cells expressing the fusion or C-deletion variant, we
were unable to detect a difference at basal conditions. In the
PDBu-treated condition, we also saw an increase in substrate
phosphorylation between the nontransfected cells and cells
expressing wild-type PKCα. Importantly, there was signifi-
cantly less PKC substrate phosphorylation in cells expressing
either the regulatory fusion or the C-deletion protein
compared with nontransfected cells. These data demonstrate
that expression of a PKC regulatory domain fusion (PKCα-
CDH8) or the isolated PKC regulatory domain (PKCα-CDH8
C.-Del.) suppresses agonist-evoked phosphorylation of PKC
substrates by a mechanism dependent on their ability to bind
DAG.
The unmasked regulatory domains of PKC have a pro-
pensity to bind the DAG-rich Golgi, leading us to address
whether the fusions may have a more pronounced effect in
suppressing PKC function at the Golgi (63). Analysis of the
mCherry-tagged PKCα-CDH8 fusion in the imaging studies
described above revealed that the fusion was more localized to
the Golgi compared with wild-type PKCα (Fig. 6F). Using the
Golgi-targeted FRET reporter GolgiCKAR (64) to monitor
PKC activity at the Golgi, overexpression of the PKCα-CDH8
fusion (red) resulted in suppression of both UTP-dependent
and PDBu-dependent activation of endogenous PKC
(Fig. 6G). Addition of the PKC inhibitor Gӧ6983 to assess the
effect of the regulatory fusion on basal activity revealed that
PKCα-CDH8 expression resulted in almost complete sup-
pression of endogenous PKC activity at the Golgi (Fig. 6H).
These results corroborate the regulatory domain fusion
sequestering DAG at the Golgi, effectively suppressing basal
activity of wild-type PKC at this compartment as well as
significantly reducing agonist-dependent activation. These
data point to the Golgi as an important intracellular
compartment in which PKC regulatory domain fusions such as
PKCα-CDH8 exert their effects, acting in a dominant-negative
manner to suppress global PKC output.Discussion
In this study, we show that PKC gene fusions result in
proteins that are loss of function in cancer. Specifically, we
report that 3’ PKC fusions, which retain the gene fragmentand inhibitor Gӧ6983 (1 μM). Graphs depict normalized FRET ratio changes
ctivity at the Golgi in COS7 cells transfected with Golgi-targeted CKAR alone
ed with inhibitor Gӧ6983 (250 nM). Graphs depict normalized FRET ratio
Protein kinase C fusions in cancerencoding the PKC catalytic domain, are loss of function
because the resulting protein is unstable and targeted for
degradation. 5’ PKC fusions, which retain the gene fragment
encoding the PKC regulatory domain, are not only loss of
function as a result of truncation of the catalytic domain but
are dominant-negative because the unmasked regulatory do-
mains sequester DAG.
Advances in bioinformatics and next-generation sequencing
technology have revolutionized our ability to appreciate the
abundance and relevance of gene fusions in cancer, particu-
larly with respect to solid tumors (38, 65). Whereas numerous
studies have investigated point mutations, deletions, and am-
plifications, relatively little attention has been given to gene
fusions. However, as exemplified by BCR-ABL1 in chronic
myeloid leukemia and ALK fusions in lung carcinomas and
mesenchymal tumors, gene fusions may play critical roles in
tumorigenesis and present as attractive targets for therapeutic
intervention (18, 66, 67). These well-characterized fusions
result in kinases with truncated regulatory domains, resulting
in constitutive activity. In addition to BCR-ABL, fusions of the
kinase domain of PKA in DNAJB1-PRKACA and the kinase
domain of various FGFR isozymes (e.g., FGFR3-TACC3, BCR-Figure 7. Model illustrating how PKC fusion proteins are loss of function in
domain and are unstable. Their inability to autoinhibit renders them sensitive t
PKC fusions encode proteins that lack the kinase domain and are thus intrins
sequestering diacylglycerol (DAG).FGFR1) drive tumorigenesis because of their unregulated ac-
tivity (68–72). Our analysis of 3’ PKC fusions reveals that these
fusions are also constitutively active due to loss of regulatory
constraints. However, the PKC catalytic domain fusions are
paradoxically loss of function because loss of autoinhibition
triggers quality control degradation pathways (Fig. 7A).
PKC in an active conformation, with the pseudosubstrate
removed from the substrate-binding cavity, is sensitive to
dephosphorylation, with the dephosphorylated species subse-
quently shunted to degradative pathways (22). Thus, aberrant
PKC that cannot be autoinhibited is subject to quality control
degradation, facilitated by PHLPP (15). PKC that has been
activated for too long, which occurs with phorbol ester treat-
ment, is dephosphorylated and also targeted for degradation
(50, 51). Overexpression studies revealed that the 3’ PKC fu-
sions are capable of being translated into functional, consti-
tutively active protein. However, their inability to retain
phosphate in mammalian cells renders them sensitive to
degradation. As a result, endogenous catalytic domain fusions
are unable to accumulate to detectable levels in cells. Although
mRNA of the fusion was detected in CRISPR-edited cells
engineered to express the TANC2-PRKCA fusion, we werecancer. A, 3’ PKC fusions encode proteins with a constitutively active kinase
o degradation, preventing accumulation to any detectable level in cells. B, 5’
ically loss of function but may also act in a dominant-negative manner by
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treatment of cells with proteasome inhibitors or inhibitors of
endosomal/lysosomal degradation and knockdown of known
E3 ligases were not sufficient to allow for accumulation of the
fusion protein. Identification of the mechanisms causing the
degradation of this aberrant PKC will provide potential targets
for restoring PKC function in cancers expressing catalytic
domain fusions.
Because 5’ PKC fusions result in proteins with a truncated
catalytic domain, they are intrinsically loss of function with
respect to PKC activity. However, we show that these regula-
tory domain fusions may have an additional role in suppress-
ing wild-type PKC activity. Overexpression of a regulatory
domain fusion suppressed endogenous PKC activity in basal
and agonist-treated conditions. Furthermore, we identified the
Golgi to be a primary site for this fusion-mediated suppression
of global PKC output, with the regulatory fusion prelocalized
to this intracellular compartment. We have previously shown
that the membrane affinity of full-length PKC is at least an
order of magnitude less than the product of the affinities of the
isolated C1B and C2 domains (73). This reduced affinity of
full-length PKC for membranes results from significant
masking of the C1 domains during the maturation of PKC to
the phosphorylated and autoinhibited species (63). Indeed, in
the context of the full-length PKC enzyme, only one of the
DAG sensors binds ligand (8, 74), with several lines of evidence
suggesting it is the C1B domain (50, 63). Furthermore, not
only do the regulatory domain fusions have two unmasked C1
domains but the C1A domain binds DAG with two orders of
magnitude higher affinity than the C1B domain (74, 75). As a
result, the isolated regulatory domain is predicted to bind
DAG with several orders of magnitude higher affinity than full-
length PKC. This enhanced affinity for DAG is likely what
directs the regulatory domain fusions to the DAG-rich Golgi,
overriding the intrinsic affinity of the C2 domain for plasma
membrane (76, 77). The PKC regulatory fusions effectively
suppressed the basal activity of endogenous PKC, consistent
with sequestration of basal DAG, and significantly reduced
agonist-evoked activity (Fig. 7B). This ability to suppress
endogenous activity is consistent with previous studies
showing that kinase-dead mutants also act in a dominant-
negative manner, suppressing global PKC output (10). Our
current results indicate that one mechanism for this
dominant-negative effect is mediated by the membrane-
targeting modules that are unmasked and can effectively
compete for ligand binding.
Functional studies revealed that basal levels of apoptosis are
reduced in CRISPR-edited cells expressing the TANC2-
PRKCA fusion compared with parental cells. This reduction
in apoptosis was also observed in CRISPR-edited cells in which
one allele of PRKCA was deleted. The similar effect on
apoptosis resulting from either deletion of PRKCA or fusion of
PRKCA with TANC2 corroborates loss of PKCα resulting in
suppressed apoptosis. These results complement previous
studies wherein a heterozygous loss-of-function mutation in
PKCβ was corrected to wild-type in DLD-1 colorectal cancer
cells through CRISPR/Cas9 gene editing (10). When these cells12 J. Biol. Chem. (2021) 296 100445were subcutaneously injected into nude mice, the resulting
tumors were smaller and exhibited greater TUNEL staining
compared with those from the parental cells. Supporting a role
of conventional PKC isozymes in promoting apoptosis, PKCα
has been found to promote apoptosis in LNCaP cells, a model
for androgen-dependent prostate cancer, through dephos-
phorylation and inactivation of Akt (78). It has also been
identified as a proapoptotic factor in other cancer contexts,
including gastric cancer and leukemia (79–81). Our findings
are thus consistent with expression of the PRKCA fusion
resulting in increased survival due to loss of one allele of wild-
type PRKCA.
Although the vast majority of PKC gene fusions are not
highly recurrent, they provide an additional general mecha-
nism for loss of PKC function in cancer. The distribution of
loss-of-function point mutations in the different domains of
PKC revealed that there are no true mutational hotspots,
indicating that there are a multitude of ways in which PKC can
be inactivated (10). Similarly, although there are many
different breakpoints among the PKC fusions, many of the
truncation events would result in loss of PKC activity. For 5’
PKC fusions, even minimal loss of the C terminus would result
in loss of PKC function as phosphorylation of the hydrophobic
motif site is necessary for catalytic competence. For 3’ PKC
fusions, partial loss of the N-terminal regulatory moiety could
also result in loss of PKC function as it would constitute a loss
in autoinhibition, which could lead to subsequent degradation.
Specifically, we showed that deletion of the pseudosubstrate in
either PKCα or PKCβII resulted in lack of phosphorylation at
the PKC priming sites, agonist-independent cellular activity,
and sensitivity to degradation, as exhibited by the fusion
proteins. Hence, for conventional isozymes of PKC, any fusion
with a minimal truncation of the 5’ end of the gene would
constitute as loss of function. Overall, due to the potential
deletion of functionally relevant domains, PKC gene fusions
have a high probability of impacting PKC activity.
Our work underscores the importance of developing ther-
apies that serve to stabilize or enhance PKC activity for cancers
in which fusions or mutations of PKC have resulted in loss of
PKC function. This is an important consideration as the initial
identification of catalytic domain fusions prompted discussion
of PKC-targeted inhibitors (24, 34, 82). Our data demonstrate,
however, that this would be detrimental. In addition to
informing the development of PKC-targeted therapeutics, PKC
fusions may also serve another important role in cancer as
biomarkers. Recurrent fusions of PRKCB and PRKCD to
membrane-associated proteins were identified in BFHs, one of
the most common neoplasms in the skin (23, 24, 26). The
recurrent fusions LAMTOR1-PRKCD and PDPN-PRKCB,
alongside CD63-PRKCD and KIRREL-PRKCA, were identified
through fluorescent in situ hybridization (FISH) and RT-
qPCR. In each of these cases, the N terminus of PKC was
replaced with membrane-binding domains of a partner protein
while retaining the PKC catalytic domain. In total, roughly 25%
of BFHs analyzed contained a PKC fusion. Moreover, tumors
containing rearrangements in PRKCB did not have rear-
rangements in ALK, previously shown to occur in the majority
Protein kinase C fusions in cancerof the epithelial subtype of BFHs. The SLC44A1-PRKCA
fusion, characterized in this study, was identified in rare
mixed neuronal-glial tumors known as PGNTs that are diffi-
cult to diagnose (35). In the initial analyses of these tumors, the
sole karyotypic abnormality was the chromosomal trans-
location t(9;17)(q31;q24), resulting in the SLC44A1-PRKCA
fusion. Out of the ten documented cases of PGNTs, the
fusion was detected in nine of them (35–37). Furthermore,
PGNTs harboring the PKC fusion lacked BRAF and FGFR1
mutations characteristic of histologically similar tumors.
Interestingly, the fusion was not detected in any of 15 PGNT
“mimics,” tumors that shared many morphological similarities
to bona fide PGNTs (37). Taken together, the recurrent PKC
fusions detected in BFHs and PGNTs and mutations and
rearrangements in known drivers appear to be mutually
exclusive, so these PKC fusions may serve as effective bio-
markers. Thus, PKC gene fusions, whether as targets or bio-
markers, may have significant therapeutic relevance in cancer.
Experimental procedures
Curation of PKC gene fusions
5’ and 3’ PKC fusions organized in Table S1, Table S2, and
graphed in Figure 1, B and C were curated from the literature
(18, 23–37) and the following online databases: the Mitelman
Database of Chromosome Aberrations and Gene Fusions in
Cancer (mitelmandatabase.isb-cgc.org), the TCGA Tumor
Fusion Gene Data Portal, ChimerDB v3.0, and COSMIC
(cancer.sanger.ac.uk) (30, 38–40). Fusions were detected in the
following cancer types: BFH, bladder urothelial carcinoma,
BRCA, cervical squamous cell carcinoma and endocervical
adenocarcinoma, colon adenocarcinoma, lymphoid neoplasm
diffuse large B-cell lymphoma, esophageal carcinoma, glio-
blastoma multiforme, head and neck squamous cell carcinoma,
clear cell renal cell carcinoma, kidney renal papillary cell car-
cinoma, acute myeloid leukemia, LGG, liver hepatocellular
carcinoma, LUAD, LUSC, medulloblastoma, ovarian serous
cystadenocarcinoma, pheochromocytoma and paraganglioma,
PGNT, prostate adenocarcinoma, sarcoma, skin cutaneous
melanoma, stomach adenocarcinoma, T-cell acute lympho-
blastic leukemia, and UCEC.
Plasmid constructs
The CKAR, CKAR2, and the Golgi-targeted C Kinase Ac-
tivity Reporter (GolgiCKAR) were previously described (46, 62,
64). Human PKCα and PKCβII were N-terminally tagged with
mCherry and YFP via Gateway cloning as previously described
(10). PKC pseudosubstrate-deleted constructs (ΔPS) were
generated by QuikChange site-directed mutagenesis (Agilent)
as previously described (15). Human TANC2-PKCα and
GGA2-PKCβII constructs were generated using Gibson As-
sembly (NEB). Constructs containing human CTL1 (SLC44A1)
and CDH8 were obtained through the DNASU plasmid re-
pository (HsCD00627280 and HsCD00403546, respectively).
The CTL1-PKCα and PKCα-CDH8 fusions were generated
through multiple iterations of PCR. Fragments of each protein
were amplified by PCR with primers containing overhanghomologous to their fusion partner. Once the fragments were
annealed, the complete fusion was amplified from the reaction
by PCR and subcloned into pcDNA3. N-deletion and C-dele-
tion constructs were generated through amplification of re-
gions of interest by PCR from constructs of wild-type PKCα
and subsequent subcloning into pcDNA3. Constructs with an
N-terminal mCherry tag were subcloned into pcDNA3 in
which mCherry had been subcloned, and constructs with an
N-terminal YFP tag were subcloned into pcDNA3 in which
YFP had been subcloned. Point mutants were generated using
QuikChange site-directed mutagenesis. The PX458 vector
encoding the Cas9 nuclease was a gift from Feng Zhang
(Plasmid # 48,138, Addgene). The pAAV-SEPT-Acceptor
vector was a gift from Todd Waldman (Plasmid #25648,
Addgene).
Antibodies and reagents
The antibodies used in this study are as listed: PKCα
(610108, BD Transduction), PKCβII (610128, BD Trans-
duction), phospho-specific PKC turn motif (PKCα/β pT638/
641, 9375S, Cell Signaling), phospho-specific PKC hydropho-
bic motif (PKCβ pS660, 9371S, Cell Signaling), HA (clone
16B12, 901515, BioLegend), Hsp90 (610418, BD Trans-
duction), TANC2 (D-11, sc-515710, Santa Cruz), caspase-3
(9662S, Cell Signaling), cleaved caspase-3 (Asp175, 9661S,
Cell Signaling), pSer PKC Substrate (2261S, Cell Signaling),
GFP (2555S, Cell Signaling), β-actin (A2228, Sigma-Aldrich),
and α-tubulin (T6074, Sigma-Aldrich). The phospho-specific
PKC activation loop antibody has been previously described
(83). The pharmacological reagents used in this study are as
listed: UTP (6701, Calbiochem), PDBu (524390, Calbiochem),
Gӧ6976 (365253, Calbiochem), Gӧ6983 (80,051–928, Calbio-
chem), BisIV (203297, Calbiochem), and etoposide (341205,
Calbiochem).
Cell culture and transfection
All cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM, 10–013-CV, Corning) containing 10% fetal
bovine serum (S11150, Atlanta Biologicals) and 1% penicillin/
streptomycin (15,140–122, Gibco) at 37 C in 5% CO2 (v/v).
Cells were periodically tested for Mycoplasma contamination
by a PCR-based method and showed no contamination (84).
Transient transfection was carried out using the Lipofectamine
3000 transfection reagent (Life Technologies), as indicated by
the manufacturer’s instructions.
Cell lysis and immunoblotting
Most cells were lysed in buffer containing 50 mM Tris (pH
7.4), 1% Triton X-100, 50 mM NaF, 10 mM Na4P2O7, 100 mM
NaCl, 5 mM EDTA, 1% deoxycholic acid that was supple-
mented with 1 mM Na3VO4, 1 mM phenylmethyl-sulfonyl
fluoride, 50 μg/ml leupeptin, 1 μM microcystin, 1 mM DTT,
and 2 mM benzamidine. Whole-cell lysates were briefly soni-
cated and boiled in sample buffer containing 250 mM Tris
HCl, 8% (w/v) SDS, 40% (v/v) glycerol, 80 μg/ml bromophenol
blue, and 2.86 M β-mercaptoethanol for 5 min at 95 C. CellsJ. Biol. Chem. (2021) 296 100445 13
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lysed in RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl,
2 mM EDTA, 1% Triton X-100, 1% deoxycholic acid, 0.1%
SDS, 10 mM NaF) supplemented with 1 mM Na3VO4, 1 mM
phenylmethyl-sulfonyl fluoride, 50 μg/ml leupeptin, 1 μM
microcystin, 1 mM DTT, and 2 mM benzamidine. Whole-cell
lysates from these studies were neither sonicated nor boiled to
minimize protein aggregation. Protein was quantified by
Bradford assay (5000006, Bio-Rad) (85). Lysates were analyzed
by SDS-PAGE and immunoblotting via chemiluminescence on
a FluorChem Q imaging system (ProteinSimple).
FRET imaging and analysis
Cells were imaged as previously described (64). As indicated,
COS7 cells were transfected with CKAR, CKAR2, or Gol-
giCKAR alone or coexpressed with mCherry-tagged PKC.
Cells were rinsed once with and imaged in Hanks’ balanced
salt solution (Corning) containing 1 mM CaCl2. Images were
acquired on a Zeiss Axiovert microscope (Carl Zeiss Micro-
Imaging, Inc) using a MicroMax digital camera (Roper-
Princeton Instruments) controlled by MetaFluor software
(Universal Imaging Corp.). Baseline values were acquired for at
least 2 min prior to reagent addition. For experiments
measuring agonist-induced activity, data were normalized to
FRET ratios after addition of inhibitor. For experiments
measuring basal activity, data were normalized to FRET ratios
at baseline. Normalized FRET ratios from at least three inde-
pendent experiments were combined, and traces represent the
average of these ratios ± SEM.
Cellular ubiquitination assay
COS7 cells were transfected with HA-tagged ubiquitin alone
or cotransfected with the indicated YFP-tagged PKC. After
24 h, cells were lysed in 50 mM Tris (pH 7.4), 1% Triton X-
100, 50 mM NaF, 10 mM Na4P2O7, 100 mM NaCl, 5 mM
EDTA, 1% deoxycholic acid that was supplemented with 1 mM
Na3VO4, 1 mM phenylmethyl-sulfonyl fluoride, 50 μg/ml
leupeptin, 1 μM microcystin, 1 mM DTT, and 2 mM benza-
midine. Lysis buffer was also supplemented with 10 mM N-
ethylmaleimide to preserve ubiquitinated species. After
centrifugation, 500 μg of the detergent-solubilized lysates was
incubated with an anti-PKCα antibody overnight at 4 C and
subsequently with protein A/G beads (Santa Cruz) for 1 h at
4 C. The immunocomplexes were washed three times with
lysis buffer (unsupplemented) and eluted by boiling in sample
buffer for 5 min at 95 C. Samples were separated by SDS-
PAGE and analyzed by immunoblotting.
Generation of CRISPR constructs for TANC2-PRKCA expression
TANC2-PRKCA is generated from the fusion of exons 1–2
of TANC2 to exons 6–17 of PRKCA. To generate the TANC2-
PRKCA gene fusion, sgRNAs targeting intron 2 of TANC2
(TANC2 gRNA: GTTGGAGTATCATCACA-CAC) and
intron 6 of PRKCA (PRKCA gRNA: GACCGGAATTCCC-
TATCCAG) were cloned into the PX458 vector. Left and right









Homology arms were cloned into the pAAV-SEPT-
Acceptor vector.
Generation of rAAV for TANC2-PRKCA expression
Recombinant AAV (rAAV) particles were generated in HEK
293T cells (ATCC CRL-3216) via cotransfection of pAAV-
SEPT containing the TANC2 and PRKCA homology arms
with the packaging plasmids pAAV-RC and pHELPER. Five
days after transfection, cells were collected in media and
subjected to three freeze/thaw cycles to release rAAV particles
followed by a 15 min spin to remove cellular debris. Released
and clarified rAAV particles were stored in media at –80 C.
Generation of CRISPR-edited cell lines for TANC2-PRKCA
expression
MDA-MB-231 cells at 50–60% confluence in a 10 cm dish
were placed in serum-free media and transfected with 6 μg
each of PX458-TANC2 sgRNA and PX458-PRKCA sgRNA
using Lipofectamine 3000. After 4 h, cells were fed with
complete media and incubated for 2 h. To transduce the cells
with rAAV, media was replaced with 50/50 media/rAAV and
incubated for 2 days. To select recombinant clones, cells were
trypsinized and collected in 120 ml of media containing 2 mg/
ml G418 and seeded at 200 μl/well into six 96-well plates.
Plates were wrapped in plastic wrap to reduce evaporation and
incubated for 20–30 days. Single colonies were expanded into
48-well plates and screened for generation of the fusion
product by PCR. To screen for recombinant clones, gDNA was
isolated using the Quick-DNA Microprep Kit (D3020, Zymo
Research) from 90% of the cells with the remaining 10%
reseeded in a 48-well plate. For clones that successfully inte-
grated the repair template, the floxed Neo cassette was
removed. To remove the cassette from the clonal cell lines,
cells were grown in a 6-well plate to 50% confluence and
treated with Adenovirus-Cre (Ad5CMVCre-eGFP high titer,
Iowa U.) in serum-free media overnight before replacing with
complete medium. Efficiency of cassette removal was verified
by splitting the well into two in the presence and absence of
2 mg/ml G418.
mRNA isolation and RT-qPCR analysis
RNA was isolated from cells using the RNeasy Mini Kit
(74104, Qiagen). Total mRNA was reverse-transcribed into
cDNA using the SuperScript III First Strand Synthesis System
(18080-051, Invitrogen), and 20 ng of the resulting cDNA was
used to perform real-time quantitative PCR. Real-time quan-
titative PCR was performed with SYBR Premix Ex TaqII
Protein kinase C fusions in cancer(RR820A, Takara Bio) and a 100 nM mix of forward and
reverse primers on a QuantStudio 3 Real-Time PCR System
(Applied Biosystems). The real-time quantitative PCR values
were normalized to the housekeeping gene actin (ACTB) using
the ΔΔCT method (86). The primer sequences used in this



















Generation of CRISPR-edited cell lines for knockout of
PKCα
To generate a PKCα knockout line, a gRNA was selected
using Synthego’s CRISPR Design Tool. A sgRNA targeting
exon 4 of PRKCA was cloned into the PX458 vector (PRKCA
gRNA 3: AGGTGGGGCTTCCGTAAGTG). MDA-MB-
231 cells were nucleofected with 2 μg of the sgRNA using the
Amaxa Nucleofector II (Amaxa) and incubated for 3 days.
Cells were then single-cell sorted for GFP-positive cells into
two 96-well plates and incubated for 20–30 days. Single
colonies were expanded into 48-well plates and screened for
potential PRKCA knockout by PCR. To screen clones, gDNA
was isolated using the Quick-DNA Microprep Kit (D3020,
Zymo Research) from 90% of the cells with the remaining
10% reseeded in a 48-well plate. An approximately 1 kb
fragment around the targeting region of the sgRNA was
amplified by PCR and submitted for Sanger sequencing
(GENEWIZ). The results were analyzed using Synthego’s
Inference of CRISPR Edits (ICE) CRISPR Analysis Tool and
validated by immunoblotting following sufficient expansion
of the clones.
Apoptosis assay
MDA-MB-231 cells were seeded at a density of 10,000 cells/
well in a 96-well plate 24 h before performing the assay.
Apoptosis was measured using the RealTime-Glo Annexin V
Apoptosis and Necrosis Assay (Promega, JA1011), which is
based on luminescence upon binding of annexin V-luciferase
to cell-surface-exposed phosphatidylserine in real time.
Luminescence was measured at the indicated times after
addition of vehicle (DMSO) or etoposide (12.5 μM) on a TecanSPARK multiwell plate reader, following manufacturer’s in-
structions. Data represent the mean ± SEM from three inde-
pendent experiments, and statistical significance was
determined using a Student’s t-test.
Data availability
All data are contained within the article.
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